Welcome to our dedicated page for KIORA PHARMACEUTICALS news (Ticker: KPRX), a resource for investors and traders seeking the latest updates and insights on KIORA PHARMACEUTICALS stock.
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapies for retinal diseases. Company news centers on its ophthalmology pipeline, including KIO-301, a molecular photoswitch program for retinitis pigmentosa, choroideremia and Stargardt disease, and KIO-104, a non-steroidal DHODH inhibitor for retinal inflammation.
Recurring updates include clinical-study publications and development progress, intellectual-property coverage for KIO-100 family formulations, collaboration and regional partnership activity, research-and-development spending, capital resources, equity financing, warrant transactions and management changes. Financial releases generally pair operating results with status reports on the company’s retinal-disease programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Kiora Pharmaceuticals (NASDAQ: KPRX) has commenced a groundbreaking Phase 1 clinical trial for KIO-301 in Melbourne, Australia, targeting Retinitis Pigmentosa (RP), a rare inherited eye disease affecting approximately 1.5 million people worldwide. The trial aims to assess the safety and tolerability of KIO-301, a molecular photoswitch designed to restore vision in RP patients. Initial results will evaluate improvements in vision and brain activity related to image processing. The collaboration involves Kiora, Accelagen, and The Royal Adelaide Hospital, aiming to establish proof-of-concept that could lead to further studies.
Kiora Pharmaceuticals (NASDAQ: KPRX) reported its Q3 2021 financial results and provided updates on its corporate activities. The company has sharpened its pipeline strategy, focusing on KIO-301, a treatment for rare diseases. Key milestones include the initiation of multiple clinical trials in 2022 and the completion of various developmental studies. Financially, Kiora raised $10.75 million in August and reported $11.1 million in cash as of September 30, 2021, indicating a significant increase from the previous year. R&D expenses rose to $1.63 million, reflecting ongoing development efforts.
Kiora Pharmaceuticals, formerly EyeGate Pharmaceuticals, has rebranded to reflect its focus on developing innovative ophthalmic therapies, including a groundbreaking treatment for Retinitis Pigmentosa. The company’s pipeline includes three key assets: KIO-101, KIO-301, and KIO-201, each targeting various eye diseases. Upcoming milestones include Phase 1b trial initiation for KIO-301 in late-stage Retinitis Pigmentosa and a pre-IND meeting with the FDA regarding KIO-201. Kiora’s strategy aims to drive value through expanded clinical development efforts.